Amgen NASDAQ: AMGN pharmaceutical company just released a report stating outstanding performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.

Study met primary endpoint of Diminishing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the premier fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being investigated for its ability to inhibit all stages of osteoclast activity by a targeted mechanism. Denosumab is being researched in a range of bone loss conditions including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its ability to defer bone metastases and inhibit and treat bone destruction across many stages of cancer.

Often referred to as the "silent epidemic", osteoporosis is a global problem illness that is increasing in significance as the world population both increases and ages. The World Health Organization (WHO) has recently claimed osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this terrible disease.

Amgen states that the financial burden of osteoporosis is compared to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Pharmacist-clinical have been developing prescriptions drugs to help patient that have serious side effects. These products are developed almost at the same time as the medications that aid in the treatment of the initial illness. The fact that information is available to help anticipate the potential effects and interactions drugs have with each other is awesome.

There are several drugs that both, prevent and treat osteoporosis. A few prescriptions slow the rate of bone loss or increase bone thickness. Even small amounts of new bone growth can diminish the danger of broken bones. It is important that you take vitamin D and calcium, eat well and exercise when you take osteoporosis prescriptions.